Chromium picolinate
Phase 1Small molecule
Chromium picolinate is one of 80 small molecule programs targeting Metabolic Syndrome. It is currently in Phase 1.
3
Indications
5
Total Trials
0
Active Trials
79
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Byetta
AstraZenecaPreclinical
Jardiance
Boehringer IngelheimPreclinical
NOVOLIN R
Novo NordiskPreclinical
Glargine
Eli LillyPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Aurlumyn
BBTG International Inc.
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Metabolic Syndrome1 trial
Chromium Picolinate for the Treatment of Metabolic Syndrome
Completed·NNational Center for Complementary and Integrative Health (NCCIH)·N/A·NCT00128154·60 enrolled
Acanthosis Nigricans1 trial
Type 2 Diabetes1 trial
Pilot Trial of Chromium-Metformin Combination in Type 2 Diabetes
Terminated·—·Phase 1·NCT00332085·40 enrolled
Unspecified2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Chromium picolinate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details